SCT-I10A

BIOLOGICAL4 trials

Sponsors

Sinocelltech Ltd.

Conditions

Advanced Solid Tumors or LymphomaColorectal CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous CarcinomaHepatocellular Carcinoma

Phase 1

Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma

Sinocelltech Ltd.Advanced Solid Tumors or Lymphoma

Start: 2018-12-13End: 2020-07-31Target: 206Updated: 2019-01-29

Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Sinocelltech Ltd.Colorectal Cancer, Esophageal Squamous Cell Carcinoma

Start: 2020-03-01End: 2022-12-01Target: 60Updated: 2020-01-18

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sinocelltech Ltd.Head and Neck Squamous Carcinoma

Start: 2022-06-15End: 2023-09-30Target: 120Updated: 2022-09-23

Phase 2

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruitingNCT04560894

Sinocelltech Ltd.Hepatocellular Carcinoma

Start: 2020-11-11End: 2024-09-30Updated: 2024-02-01

Related Papers

Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial

Cancer2025-08-15

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

2025-08-062 citations

Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody.

2025-01-30

SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.

Journal of Clinical Oncology2024-06-0112 citations

Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer

Cancer Biology and Medicine2023-12-238 citations